Table 1.
Patient and tumor characteristics at baseline
| Characteristics | TOR120 | EXE | |
|---|---|---|---|
| Number of the patients |
46 |
45 |
|
| Age; median (range) |
63 (51–87) |
62 (49–87) |
|
| Follow-up period (weeks); median (range) |
69 (13–144) |
81 (13–160) |
|
| Time elapsed after menopause (years); median (range) |
13 (2–37) |
13 (1–37) |
|
| Body Mass Index; median (range) |
22.9 (18.0-35.2) |
23.4 (27.7-35.4) |
|
| DFI in recurrent cases (months); median (range) |
70 (5–188) |
60 (1–189) |
|
| Estrogen Receptor status |
Positive |
45 |
42 |
| Negative |
0 |
1 |
|
| Unknown |
1 |
2 |
|
| Progesterone Receptor status |
Positive |
27 |
31 |
| Negative |
17 |
11 |
|
| Unknown |
2 |
3 |
|
| HER2 status |
Negative |
43 |
40 |
| Positive |
1 |
1 |
|
| Unknown |
2 |
4 |
|
| Main metastatic lesion | |||
| Visceral disease (main organ) |
Lung |
10 |
10 |
| Liver |
7 |
6 |
|
| Pleura |
5 |
3 |
|
| Non-visceral disease |
Bone |
9 (20%) |
14 (31%) |
| Soft tissue |
15 |
12 |
|
| Performance status (cases) |
0,1 |
45 |
44 |
| 2 |
1 |
1 |
|
| No. of previous therapies (%) |
1 |
28 |
29 |
| 2 |
41 |
42 |
|
| 3 |
24 |
18 |
|
| ≥4 |
9 |
11 |
|
| Previous aromatase inhibitor (%) |
Anastrozole |
48 |
47 |
| Letrozole |
52 |
53 |
|
| Previous treatment with tamoxifen (%) |
21 |
24 |
|
| Previous chemotherapy (%) |
44 |
38 |
|
| Sensitivity to previous aromatase inhibitor treatment; | |||
| Clinical Benefit Rate (%) |
17/23 (74%) |
20/30 (67%) |
|
| Duration of previous aromatase inhibitor(months); median (range) | 17.1 (2.0-80.8) | 17.6 (2.4-65.3) | |